Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.


  • Dec 26, 2014 Contribution to the Personalized Healthcare for Melanoma
    Approval for BRAF inhibitor, “Zelboraf®” and its Companion Diagnostic, “cobas® 4800 BRAF V600 Mutation Test.”
    [PDF 119KB]
  • Dec 25, 2014 Chugai Wins the First Instance of the
    Patent Infringement Lawsuit for Oxarol® Ointment
    [PDF 107KB]
  • Dec 24, 2014 Participation in the Global Health Innovative Technology Fund
    (GHIT Fund)
    [PDF 120KB]
  • Dec 19, 2014 Anti-Cancer Agent “Xeloda®
    Application for Approval of Additional Indication of “Postoperative Adjuvant Chemotherapy for Gastric Cancer”
    [PDF 123KB]
  • Dec 09, 2014 Complete Phase I Results of Chugai’s Bispecific Antibody "ACE910" Released at the American Society of Hematology Meeting
    [PDF 155KB]
    Creating value beyond our conventional ideas and expectations
    [PDF 237KB]
  • Nov 26, 2014 Personnel Changes
    [PDF 140KB]
  • Nov 07, 2014 Phase I Data of Chugai’s Bispecific Antibody "ACE910" to be Presented at The American Society of Hematology Meeting
    [PDF 93KB]
  • Oct 29, 2014 Supply Plan of "Tamiflu®" Anti-influenza Drug for the 2014-2015 Season
    [PDF 143KB]
  • Oct 17, 2014 Fulfilling the Philosophy of Para-Sports Aimed at “Increase of Vitality for Convivial Society”
    - New Contents Released on the Chugai Website -
    [PDF 113KB]
  • Oct 16, 2014 F. Hoffmann-La Roche Announces Third Quarter Sales 2014
    [PDF 76KB]
  • Oct 01, 2014 Chugai to Join “BioJapan2014” as an Official Sponsor
    The Largest Biotechnology Partnering Event in Asia
    [PDF 340KB]
  • Sep 25, 2014 Chugai Receives Two Awards in
    “Commendation of Companies Promoting Gender Equality and Work-Family Balance 2014”
    Hosted by the Ministry of Health, Labour and Welfare
    [PDF 217KB]
  • Sep 22, 2014 Bisphosphonate Antiresorptive Agent,
    Ibandronate Sodium Hydrate Oral Agent,
    Demonstrates Efficacy in Osteoporosis in Phase III Trial
    [PDF 21KB]
  • Sep 19, 2014 Chugai Debuts on Dow Jones Sustainability Asia Pacific Index,
    an Index for Socially Responsible Investment
    [PDF 189KB]
  • Sep 08, 2014 Roche’s RoACTEMRA Receives EU Approval for Use in Patients
    with Early Rheumatoid Arthritis (RA)
    [PDF 237KB]
  • Sep 08, 2014 30th Contribution of Para-transit Vehicles to Welfare Services
    A Total of 203 Vehicles will be Donated
    [PDF 224KB]
  • Sep 05, 2014 Launch of the Anti-Cancer Agent / ALK Inhibitor “Alecensa®
    [PDF 199KB]
  • Aug 29, 2014 Results of Japanese Phase II Clinical Trial for
    Non-Small Cell Lung Cancer with EGFR Mutations was
    Published Online on “The Lancet Oncology”
    [PDF 181KB]
  • Aug 28, 2014 Amendment of Business Arrangements Regarding
    the Conditions for Out-Licensing Chugai Products
    Based on the Strategic Alliance between Chugai and Roche
    [PDF 178KB]
  • Aug 27, 2014 Disclosure of Information on Chugai’s 2013 Corporate Activities
    Based on Transparency Guidelines
    [PDF 176KB]
  • Aug 16, 2014 Regarding a Certain Media Report
    [PDF 16KB]
  • Jul 24, 2014 Organizational and Personnel Changes
    [PDF 200KB]
  • Jul 24, 2014 F. Hoffmann-La Roche Announces Half Year Results 2014
    [PDF 21KB]
  • Jul 17, 2014 Helsinn Group and Chugai Pharma Marketing Enter into Agreement for
    Marketing Rights of Netupitant-Palonosetron Fixed-Dose Combination
    (NEPA) in The UK and Ireland and for Palonosetron Monotherapy in The UK
    [PDF 54KB]
  • Jul 15, 2014 PharmaMar and Chugai Pharma Marketing Enter into a License and
    Commercialization Agreement in Europe for Aplidin®
    [PDF 58KB]
  • Jul 04, 2014 An Anti-Cancer Agent, ALK Inhibitor “Alecensa®,”
    Approved for the Treatment of ALK Fusion Gene Positive
    Unresectable, Recurrent / Advanced Non-Small Cell Lung Cancer
    [PDF 183KB]
  • Jul 02, 2014 “Along with Antibody Drugs” — A Movie Newly Posted on Chugai’s
    Website, Including Easy-to-understand Information on Antibody
    Engineering Technologies as Chugai’s Strength
    [PDF 311KB]
  • Jun 13, 2014 Chugai Offers Biology Laboratory Class
    for Elementary School Students
    [PDF 234KB]
  • May 23, 2014 Chugai and Roche Enter a License Agreement for
    Chugai’s Proprietary Innovative Antibody Engineering Technologies
    [PDF 207KB]
  • May 12, 2014 Determination of Terms and Conditions of Stock Options
    (Stock Acquisition Rights)
    [PDF 36KB]
  • Apr 28, 2014 Roche Receives EU Approval for New Subcutaneous
    Formulation of RoACTEMRA
    Providing more Treatment Flexibility
    for Patients with Moderate to Severe Rheumatoid Arthritis
    [PDF 200KB]
  • Apr 25, 2014 Chugai Pharma USA Announces Appointment of
    Chief Medical Officer
    [PDF 180KB]
  • Apr 24, 2014 Issuance of Stock Options (Stock Acquisition Rights)
    [PDF 76KB]
  • Apr 17, 2014 Launch of the Anti-Cancer Agent “Kadcyla®
    [PDF 214KB]
  • Apr 15, 2014 F. Hoffmann-La Roche Announces First Quarter Sales 2014
    [PDF 21KB]
  • Apr 09, 2014 New Drug Application Filed for “Vemurafenib”
    for the Treatment of Melanoma with BRAFV600 Mutation
    and a Companion Diagnostic to Detect the BRAF Mutation
    [PDF 64KB]
  • Mar 20, 2014 Chugai to Participate in
    High-Quality Protein Crystal Growth Experiment
    in the International Space Station, “Kibo,” as Private Company
    [PDF 214KB]
  • Feb 10, 2014 Chugai Won the Award for Excellence
    in the 16th Nikkei Annual Report Awards
    [PDF 190KB]
  • Jan 30, 2014 Personnel Changes
    [PDF 130KB]
  • Jan 30, 2014 F. Hoffmann-La Roche Announces Financial Results for Fiscal 2013
    [PDF 45KB]
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top